Also listed on Espero Biopharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Feb 9, 2027 · High confidence
20-year base term ended Jul 14, 2026
Held by Xyra, LLC
Filed Jul 14, 2006 as application 11/457,719 · Granted Mar 3, 2009
Base term plus 210 days of patent term adjustment (USPTO delay)
Today
2006
2027
Clock starts
Jul 14, 2006
Jul 14, 2006
Term ends
Feb 9, 2027
Feb 9, 2027
Granted
Mar 3, 2009
Mar 3, 2009
base term
patent term adjustment
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
210
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
This patent's term runs 210 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 14, 2006, when this application, 11/457,719, was filed | Jul 14, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +210 days, USPTO patent term adjustment record | Feb 9, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 9, 2027 | High confidence |
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 27, 2006 Reel 18551, frame 219 | Druzgala, Pascal; Tien, Jien-heh J; Cooper, Arthur J; Beoker, Cyrus | Aryx Therapeutics | Assignment of Assignor's Interest |
| Oct 29, 2007 Reel 20024, frame 545 | Aryx Therapeutics | Aryx Therapeutics, Inc. | Assignment of Assignor's Interest |
| Oct 18, 2010 Reel 25150, frame 379 | Aryx Therapeutics, Inc. | Ayer Capital Partners Master Fund, L.P.; Mpm Bioventures Iii, L.p.; Mpm Bioventures Iii-qp, L.p.; MPM Bioventures III GmbH & Co. Beteiligungs KG; MPM Bioventures III Parallel Fund, L.P.; Ayer Capital Partners Kestrel Fund, L.P.; MPM Asset Management Investors 2002 Bviii LLC | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | Ayer Capital Partners Master Fund, L.P. | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | Mpm Bioventures Iii, L.p. | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | Mpm Bioventures Iii-qp, L.p. | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | MPM Bioventures III GmbH & Co. Beteiligungs KG | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | MPM Bioventures III Parallel Fund, L.P. | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | Ayer Capital Partners Kestrel Fund, L.P. | Security Agreement |
| Oct 18, 2010 reel/frame not recorded | Aryx Therapeutics, Inc. | MPM Asset Management Investors 2002 Bviii LLC | Security Agreement |
| Oct 1, 2012 Reel 29057, frame 220 | Aryx Therapeutics, Inc. | Armetheon, Inc. | Assignment of Assignor's Interest |
| Feb 6, 2013 Reel 29767, frame 524 | Ayer Capital Partners Master Fund, L.P.; Mpm Bioventures Iii, L.p.; Mpm Bioventures Iii-qp, L.p.; MPM Bioventures III GmbH & Co. Beteiligungs KG; MPM Bioventures III Parallel Fund, L.P.; Ayer Capital Partners Kestrel Fund, L.P.; MPM Asset Management Investors 2002 Bviii LLC | Aryx Therapeutics, Inc. | Release of Security Interest |
| Apr 16, 2019 Reel 48918, frame 544 | Espero Biopharma, Inc. | Horizon Technology Finance Corporation | Security Interest |
| Jul 23, 2020 Reel 53293, frame 930 | Armetheon, Inc. | Espero Biopharma, Inc. | Change of Name |
| Oct 23, 2020 Reel 54150, frame 11 | Espero Biopharma, Inc. | Hesp LLC | Assignment of Assignor's Interest |
| Jun 4, 2025 Reel 71313, frame 627 | Hesp LLC | Xyra, LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Feb 2027
Term ends Feb 9, 2027. No further fees fall due before then
Note
The 210 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
2
later US patents cite this one
That is below the median of utility patents granted in 2009 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.